776 results on '"Walker, Zuzana"'
Search Results
2. Research criteria for the diagnosis of prodromal dementia with Lewy bodies
3. The Effect of Mindfulness-based Programs on Cognitive Function in Adults: A Systematic Review and Meta-analysis
4. Quantification supports amyloid-PET visual assessment of challenging cases: results from the AMYPAD-DPMS study
5. Effects of a mindfulness-based versus a health self-management intervention on objective cognitive performance in older adults with subjective cognitive decline (SCD): a secondary analysis of the SCD-Well randomized controlled trial
6. SPECT/PET Findings in Dementia with Lewy Bodies
7. Predicting progression to Alzheimer's disease dementia using cognitive measures
8. Clinical and cost-effectiveness of DREAMS START (Dementia RElAted Manual for Sleep; STrAtegies for RelaTives) for people living with dementia and their carers: a study protocol for a parallel multicentre randomised controlled trial
9. Diagnosis and management of dementia with Lewy bodies
10. Worry and ruminative brooding: associations with cognitive and physical health in older adults.
11. Investigating reliable amyloid accumulation in Centiloids: Results from the AMYPAD Prognostic and Natural History Study.
12. Sex differences in brain atrophy in dementia with Lewy bodies
13. Differential dementia diagnosis using event‐based modelling: Alzheimer’s disease versus Dementia with Lewy Bodies
14. Dysfunctional cerebral glucose transport in Alzheimer’s Disease
15. The association between Aβ aggregation and age depends on APOE genotype: Findings from the AMYPAD cohort
16. A Centiloid cut‐off to help predict true amyloid accumulation
17. MRI CHANGES FOLLOWING TREATMENT OF GLP‐1 ANALOGUE, LIRAGLUTIDE IN ALZHEIMER’S DISEASE
18. AMYPAD: Correlation of Amyloid PET results with anxiety and depressive symptoms in SCD+, MCI and dementia patients
19. APPLE‐Tree remote secondary dementia prevention; opportunities for scalable public health interventions to reduce dementia risk
20. Predicting progression to Alzheimer’s disease dementia using cognitive measures: findings from the Essex Memory Clinic
21. Magnetic Resonance Spectroscopy metabolites as biomarkers of Alzheimer’s Disease
22. Progress on the Development of the Lewy Body Dementia‐Domain Rating Scale
23. Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer’s subjects?
24. A signature pattern of cortical atrophy in dementia with Lewy bodies: A study on 333 patients from the European DLB consortium
25. AMYPAD Diagnostic and Patient Management Study: Rationale and design
26. Cognitive decline in Alzheimer’s: faster in early onset than late onset disease
27. SPECT/PET Findings in Dementia with Lewy Bodies
28. Dopamine Transporter Imaging
29. The SCD-Well randomized controlled trial: Effects of a mindfulness-based intervention versus health education on mental health in patients with subjective cognitive decline (SCD)
30. Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease
31. Correction to: Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study)
32. Dementia with Lewy Bodies
33. Dementia with Lewy bodies : the investigation of pre- and post-synaptic dopaminergic receptors with SPET
34. Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients: The AMYPAD-DPMS Randomized Clinical Trial
35. Analysis of Psychological Symptoms Following Disclosure of Amyloid-Positron Emission Tomography Imaging Results to Adults With Subjective Cognitive Decline
36. Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders
37. Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia
38. Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer’s disease
39. Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia
40. Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington’s disease
41. Clinical utility of FDG-PET for the clinical diagnosis in MCI
42. Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia
43. Crop Filling: a pipeline for repairing memory clinic MRI corrupted by partial brain coverage
44. SPECT/PET Findings in Lewy Body Dementia
45. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study)
46. The amyloid imaging for the prevention of Alzheimer's disease consortium: A European collaboration with global impact
47. Lewy body dementias
48. A Double-Blind Randomized Placebo-Controlled Withdrawal Trial Comparing Memantine and Antipsychotics for the Long-Term Treatment of Function and Neuropsychiatric Symptoms in People With Alzheimer's Disease (MAIN-AD)
49. Steps towards the implementation of amyloid‐PET in memory clinics: AMYPAD Diagnostic and Patient Management Study
50. The Deep Dementia Phenotyping (DEMON) Network: A global platform for innovation using data science and artificial intelligence
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.